Status:
COMPLETED
Open-label Study With Bosentan in Interstitial Lung Disease
Lead Sponsor:
Actelion
Conditions:
Interstitial Lung Disease
Scleroderma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.
Eligibility Criteria
Inclusion
- To have completed the 12-month treatment period of the AC-052-330/BUILD 2.
- Women should not be pregnant
- Women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception
- Signed informed consent prior to initiation of any study-mandated procedure
Exclusion
- Any major violation of the protocol AC-052-330.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT00319033
Start Date
July 1 2004
End Date
February 1 2006
Last Update
February 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.